{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T13:07:35Z","timestamp":1787317655599,"version":"build-2736575974"},"reference-count":42,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,2]],"date-time":"2025-07-02T00:00:00Z","timestamp":1751414400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Health Systems Research Institute, Thailand","award":["67-095"],"award-info":[{"award-number":["67-095"]}]},{"name":"Thailand Science Research and Innovation Fund Chulalongkorn University, Thailand","award":["HEA663000052"],"award-info":[{"award-number":["HEA663000052"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-025-05605-w","type":"journal-article","created":{"date-parts":[[2025,7,1]],"date-time":"2025-07-01T21:46:59Z","timestamp":1751406419000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Somatic mutations in the TG and RELA genes specific for radioiodine-refractory thyroid cancer"],"prefix":"10.1038","volume":"15","author":[{"given":"Chanan","family":"Sukprakun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pattarin","family":"Nuwongsri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siraprapa","family":"Tongkobpetch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chalurmpon","family":"Srichomthong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chanida","family":"Vinayanuwattikun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Somboon","family":"Keelawat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supavadee","family":"Jantasuwan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Napadon","family":"Tangjaturonrasme","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pasurachate","family":"Samorn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vorasuk","family":"Shotelersuk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Supatporn","family":"Tepmongkol","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,2]]},"reference":[{"key":"5605_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel, R. L., Giaquinto, A. N. & Jemal, A. Cancer statistics, 2024. CA Cancer J. Clin. 74, 12\u201349. https:\/\/doi.org\/10.3322\/caac.21820 (2024).","journal-title":"CA Cancer J. Clin."},{"key":"5605_CR2","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.1016\/S0140-6736(13)60109-9","volume":"381","author":"M Xing","year":"2013","unstructured":"Xing, M., Haugen, B. R. & Schlumberger, M. Progress in molecular-based management of differentiated thyroid cancer. Lancet 381, 1058\u20131069. https:\/\/doi.org\/10.1016\/S0140-6736(13)60109-9 (2013).","journal-title":"Lancet"},{"key":"5605_CR3","doi-asserted-by":"publisher","unstructured":"Haugen, B. R. et al. American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer. Thyroid 26, 1-133 (2016). (2015). https:\/\/doi.org\/10.1089\/thy.2015.0020","DOI":"10.1089\/thy.2015.0020"},{"key":"5605_CR4","doi-asserted-by":"crossref","first-page":"15N","DOI":"10.2967\/jnumed.121.262402","volume":"63","author":"AM Avram","year":"2022","unstructured":"Avram, A. M. et al. SNMMI procedure standard\/eanm practice guideline for nuclear medicine evaluation and therapy of differentiated thyroid cancer: abbreviated version. J. Nucl. Med. 63, 15\u00a0N\u201335\u00a0N (2022).","journal-title":"J. Nucl. Med."},{"key":"5605_CR5","doi-asserted-by":"publisher","first-page":"2892","DOI":"10.1210\/jc.2005-2838","volume":"91","author":"C Durante","year":"2006","unstructured":"Durante, C. et al. Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J. Clin Endocrinol. Metab. 91, 2892\u20132899. https:\/\/doi.org\/10.1210\/jc.2005-2838 (2006).","journal-title":"J. Clin Endocrinol. Metab"},{"key":"5605_CR6","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S0140-6736(14)60421-9","volume":"384","author":"MS Brose","year":"2014","unstructured":"Brose, M. S. et al. Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet 384, 319\u2013328. https:\/\/doi.org\/10.1016\/S0140-6736(14)60421-9 (2014).","journal-title":"Lancet"},{"key":"5605_CR7","doi-asserted-by":"publisher","first-page":"621","DOI":"10.1056\/NEJMoa1406470","volume":"372","author":"M Schlumberger","year":"2015","unstructured":"Schlumberger, M. et al. Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. N Engl. J. Med. 372, 621\u2013630. https:\/\/doi.org\/10.1056\/NEJMoa1406470 (2015).","journal-title":"N Engl. J. Med."},{"key":"5605_CR8","doi-asserted-by":"publisher","first-page":"1126","DOI":"10.1016\/S1470-2045(21)00332-6","volume":"22","author":"MS Brose","year":"2021","unstructured":"Brose, M. S. et al. Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. 22, 1126\u20131138. https:\/\/doi.org\/10.1016\/S1470-2045(21)00332-6 (2021).","journal-title":"Lancet Oncol."},{"key":"5605_CR9","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1056\/NEJMoa1209288","volume":"368","author":"AL Ho","year":"2013","unstructured":"Ho, A. L. et al. Selumetinib-enhanced radioiodine uptake in advanced thyroid cancer. N Engl. J. Med. 368, 623\u2013632. https:\/\/doi.org\/10.1056\/NEJMoa1209288 (2013).","journal-title":"N Engl. J. Med."},{"key":"5605_CR10","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1111\/j.1365-2265.2011.04032.x","volume":"75","author":"EC Morari","year":"2011","unstructured":"Morari, E. C. et al. Use of sodium iodide symporter expression in differentiated thyroid carcinomas. Clin. Endocrinol. (Oxf). 75, 247\u2013254. https:\/\/doi.org\/10.1111\/j.1365-2265.2011.04032.x (2011).","journal-title":"Clin. Endocrinol. (Oxf)"},{"key":"5605_CR11","doi-asserted-by":"publisher","first-page":"623182","DOI":"10.3389\/fendo.2021.623182","volume":"12","author":"CJ Gomes-Lima","year":"2021","unstructured":"Gomes-Lima, C. J. et al. Do molecular profiles of primary versus metastatic radioiodine refractory differentiated thyroid Cancer differ?? Front. Endocrinol. (Lausanne). 12, 623182. https:\/\/doi.org\/10.3389\/fendo.2021.623182 (2021).","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"5605_CR12","doi-asserted-by":"publisher","first-page":"1231","DOI":"10.1210\/clinem\/dgad697","volume":"109","author":"Z Mu","year":"2024","unstructured":"Mu, Z. et al. Characterizing genetic alterations related to radioiodine avidity in metastatic thyroid Cancer. J. Clin. Endocrinol. Metab. 109, 1231\u20131240. https:\/\/doi.org\/10.1210\/clinem\/dgad697 (2024).","journal-title":"J. Clin. Endocrinol. Metab."},{"key":"5605_CR13","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1089\/thy.2008.0056","volume":"18","author":"S Tepmongkol","year":"2008","unstructured":"Tepmongkol, S., Keelawat, S., Honsawek, S. & Ruangvejvorachai, P. Rosiglitazone effect on radioiodine uptake in thyroid carcinoma patients with high thyroglobulin but negative total body scan: a correlation with the expression of peroxisome proliferator-activated receptor-gamma. Thyroid 18, 697\u2013704. https:\/\/doi.org\/10.1089\/thy.2008.0056 (2008).","journal-title":"Thyroid"},{"key":"5605_CR14","doi-asserted-by":"publisher","first-page":"258","DOI":"10.2967\/jnumed.116.180240","volume":"58","author":"X Yang","year":"2017","unstructured":"Yang, X. et al. TERT promoter mutation predicts Radioiodine-Refractory character in distant metastatic differentiated thyroid Cancer. J. Nucl. Med. 58, 258\u2013265. https:\/\/doi.org\/10.2967\/jnumed.116.180240 (2017).","journal-title":"J. Nucl. Med."},{"key":"5605_CR15","doi-asserted-by":"publisher","first-page":"3959","DOI":"10.2147\/OTT.S308910","volume":"14","author":"T Anekpuritanang","year":"2021","unstructured":"Anekpuritanang, T. et al. The association between radioiodine refractory in papillary thyroid carcinoma, sodium\/iodide symporter expression, and BRAF (V600E) mutation. Onco Targets Ther. 14, 3959\u20133969. https:\/\/doi.org\/10.2147\/OTT.S308910 (2021).","journal-title":"Onco Targets Ther."},{"key":"5605_CR16","doi-asserted-by":"publisher","unstructured":"Li, X. & Kwon, H. The impact of BRAF mutation on the recurrence of papillary thyroid carcinoma: A Meta-Analysis. Cancers (Basel). 12. https:\/\/doi.org\/10.3390\/cancers12082056 (2020).","DOI":"10.3390\/cancers12082056"},{"key":"5605_CR17","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1159\/000443032","volume":"38","author":"Q Zhang","year":"2016","unstructured":"Zhang, Q. et al. Meta-Analyses of association between BRAF(V600E) mutation and clinicopathological features of papillary thyroid carcinoma. Cell. Physiol. Biochem. 38, 763\u2013776. https:\/\/doi.org\/10.1159\/000443032 (2016).","journal-title":"Cell. Physiol. Biochem."},{"key":"5605_CR18","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1007\/s12022-022-09707-3","volume":"33","author":"ZW Baloch","year":"2022","unstructured":"Baloch, Z. W. et al. Overview of the 2022 WHO classification of thyroid neoplasms. Endocr. Pathol. 33, 27\u201363. https:\/\/doi.org\/10.1007\/s12022-022-09707-3 (2022).","journal-title":"Endocr. Pathol."},{"key":"5605_CR19","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1007\/s40618-018-0919-8","volume":"42","author":"J Simoes-Pereira","year":"2019","unstructured":"Simoes-Pereira, J. et al. The role of EIF1AX in thyroid cancer tumourigenesis and progression. J. Endocrinol. Invest. 42, 313\u2013318. https:\/\/doi.org\/10.1007\/s40618-018-0919-8 (2019).","journal-title":"J. Endocrinol. Invest."},{"key":"5605_CR20","doi-asserted-by":"publisher","first-page":"42445","DOI":"10.18632\/oncotarget.6442","volume":"6","author":"M Duquette","year":"2015","unstructured":"Duquette, M. et al. Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to Vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model. Oncotarget 6, 42445\u201342467. https:\/\/doi.org\/10.18632\/oncotarget.6442 (2015).","journal-title":"Oncotarget"},{"key":"5605_CR21","doi-asserted-by":"publisher","first-page":"454","DOI":"10.1038\/s41419-023-05981-z","volume":"14","author":"X Li","year":"2023","unstructured":"Li, X. et al. STAG2 inactivation reprograms glutamine metabolism of BRAF-mutant thyroid cancer cells. Cell. Death Dis. 14, 454. https:\/\/doi.org\/10.1038\/s41419-023-05981-z (2023).","journal-title":"Cell. Death Dis."},{"key":"5605_CR22","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1007\/978-3-030-55031-8_10","volume":"1287","author":"R Guenter","year":"2021","unstructured":"Guenter, R., Patel, Z. & Chen, H. Notch signaling in thyroid Cancer. Adv. Exp. Med. Biol. 1287, 155\u2013168. https:\/\/doi.org\/10.1007\/978-3-030-55031-8_10 (2021).","journal-title":"Adv. Exp. Med. Biol."},{"key":"5605_CR23","doi-asserted-by":"publisher","first-page":"255","DOI":"10.3233\/CBM-190871","volume":"28","author":"IV Iancu","year":"2020","unstructured":"Iancu, I. V. et al. Alterations of regulatory factors and DNA methylation pattern in thyroid cancer. Cancer Biomark. 28, 255\u2013268. https:\/\/doi.org\/10.3233\/CBM-190871 (2020).","journal-title":"Cancer Biomark."},{"key":"5605_CR24","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1158\/1078-0432.CCR-18-0373","volume":"24","author":"N Pozdeyev","year":"2018","unstructured":"Pozdeyev, N. et al. Genetic analysis of 779 advanced differentiated and anaplastic thyroid cancers. Clin. Cancer Res. 24, 3059\u20133068. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0373 (2018).","journal-title":"Clin. Cancer Res."},{"key":"5605_CR25","doi-asserted-by":"publisher","first-page":"e31705","DOI":"10.1097\/MD.0000000000031705","volume":"101","author":"C Xie","year":"2022","unstructured":"Xie, C. et al. BRCA2 gene mutation in cancer. Med. (Baltim). 101, e31705. https:\/\/doi.org\/10.1097\/MD.0000000000031705 (2022).","journal-title":"Med. (Baltim)."},{"key":"5605_CR26","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1089\/thy.2005.15.1079","volume":"15","author":"A Hishinuma","year":"2005","unstructured":"Hishinuma, A., Fukata, S., Kakudo, K., Murata, Y. & Ieiri, T. High incidence of thyroid cancer in long-standing goiters with thyroglobulin mutations. Thyroid 15, 1079\u20131084. https:\/\/doi.org\/10.1089\/thy.2005.15.1079 (2005).","journal-title":"Thyroid"},{"key":"5605_CR27","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1089\/thy.2010.0384","volume":"21","author":"A Akdi","year":"2011","unstructured":"Akdi, A. et al. Common variants of the thyroglobulin gene are associated with differentiated thyroid cancer risk. Thyroid 21, 519\u2013525. https:\/\/doi.org\/10.1089\/thy.2010.0384 (2011).","journal-title":"Thyroid"},{"key":"5605_CR28","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1089\/thy.2018.0687","volume":"29","author":"Z Hurst","year":"2019","unstructured":"Hurst, Z. et al. Risk haplotypes uniquely associated with Radioiodine-Refractory thyroid Cancer patients of high African ancestry. Thyroid 29, 530\u2013539. https:\/\/doi.org\/10.1089\/thy.2018.0687 (2019).","journal-title":"Thyroid"},{"key":"5605_CR29","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1210\/er.2001-0029","volume":"24","author":"O Dohan","year":"2003","unstructured":"Dohan, O. et al. The sodium\/iodide symporter (NIS): characterization, regulation, and medical significance. Endocr. Rev. 24, 48\u201377. https:\/\/doi.org\/10.1210\/er.2001-0029 (2003).","journal-title":"Endocr. Rev."},{"key":"5605_CR30","doi-asserted-by":"publisher","first-page":"6114","DOI":"10.1210\/en.2012-1567","volume":"153","author":"M Nazar","year":"2012","unstructured":"Nazar, M., Nicola, J. P., Velez, M. L., Pellizas, C. G. & Masini-Repiso, A. M. Thyroid peroxidase gene expression is induced by lipopolysaccharide involving nuclear factor (NF)-kappaB p65 subunit phosphorylation. Endocrinology 153, 6114\u20136125. https:\/\/doi.org\/10.1210\/en.2012-1567 (2012).","journal-title":"Endocrinology"},{"key":"5605_CR31","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1590\/2359-3997000000245","volume":"61","author":"A Schmidt","year":"2017","unstructured":"Schmidt, A., Iglesias, L., Klain, M., Pitoia, F. & Schlumberger, M. J. Radioactive iodine-refractory differentiated thyroid cancer: an uncommon but challenging situation. Arch. Endocrinol. Metab. 61, 81\u201389. https:\/\/doi.org\/10.1590\/2359-3997000000245 (2017).","journal-title":"Arch. Endocrinol. Metab."},{"key":"5605_CR32","doi-asserted-by":"publisher","first-page":"1573","DOI":"10.1007\/s40618-024-02352-z","volume":"47","author":"L Schubert","year":"2024","unstructured":"Schubert, L. et al. Clinico-pathological factors associated with radioiodine refractory differentiated thyroid carcinoma status. J. Endocrinol. Invest. 47, 1573\u20131581. https:\/\/doi.org\/10.1007\/s40618-024-02352-z (2024).","journal-title":"J. Endocrinol. Invest."},{"key":"5605_CR33","unstructured":"Biosciences, P. pbmm2 aligner, https:\/\/github.com\/PacificBiosciences\/pbmm2."},{"key":"5605_CR34","doi-asserted-by":"publisher","first-page":"983","DOI":"10.1038\/nbt.4235","volume":"36","author":"R Poplin","year":"2018","unstructured":"Poplin, R. et al. A universal SNP and small-indel variant caller using deep neural networks. Nat. Biotechnol. 36, 983\u2013987. https:\/\/doi.org\/10.1038\/nbt.4235 (2018).","journal-title":"Nat. Biotechnol."},{"key":"5605_CR35","unstructured":"Bozeman, M. VarSeq\u2122 v.2.4.0. http:\/\/www.goldenhelix.com"},{"key":"5605_CR36","doi-asserted-by":"publisher","first-page":"355","DOI":"10.1016\/j.pharmthera.2012.06.007","volume":"135","author":"T Kogai","year":"2012","unstructured":"Kogai, T. & Brent, G. A. The sodium iodide symporter (NIS): regulation and approaches to targeting for cancer therapeutics. Pharmacol. Ther. 135, 355\u2013370. https:\/\/doi.org\/10.1016\/j.pharmthera.2012.06.007 (2012).","journal-title":"Pharmacol. Ther."},{"key":"5605_CR37","doi-asserted-by":"publisher","first-page":"215","DOI":"10.3803\/EnM.2019.34.3.215","volume":"34","author":"J Liu","year":"2019","unstructured":"Liu, J., Liu, Y., Lin, Y. & Liang, J. Radioactive Iodine-Refractory differentiated thyroid Cancer and redifferentiation therapy. Endocrinol. Metab. (Seoul). 34, 215\u2013225. https:\/\/doi.org\/10.3803\/EnM.2019.34.3.215 (2019).","journal-title":"Endocrinol. Metab. (Seoul)"},{"key":"5605_CR38","doi-asserted-by":"publisher","unstructured":"Li, H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. ArXiv 1303. https:\/\/doi.org\/10.48550\/arXiv.1303.3997 (2013).","DOI":"10.48550\/arXiv.1303.3997"},{"key":"5605_CR39","doi-asserted-by":"publisher","first-page":"111011","DOI":"10.1002\/0471250953.bi1110s43","volume":"43","author":"G Van der Auwera","year":"2013","unstructured":"Van der Auwera, G. et al. From FastQ data to high confidence variant calls: the genome analysis toolkit best practices pipeline. Curr. Protoc. Bioinf. 43, 111011\u2013111033. https:\/\/doi.org\/10.1002\/0471250953.bi1110s43 (2013).","journal-title":"Curr. Protoc. Bioinf."},{"key":"5605_CR40","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1038\/s41592-018-0001-7","volume":"15","author":"FJ Sedlazeck","year":"2018","unstructured":"Sedlazeck, F. J. et al. Accurate detection of complex structural variations using single-molecule sequencing. Nat. Methods. 15, 461\u2013468. https:\/\/doi.org\/10.1038\/s41592-018-0001-7 (2018).","journal-title":"Nat. Methods"},{"key":"5605_CR41","doi-asserted-by":"publisher","first-page":"1571","DOI":"10.1038\/s41587-023-02024-y","volume":"42","author":"M Smolka","year":"2024","unstructured":"Smolka, M. et al. Detection of mosaic and population-level structural variants with Sniffles2. Nat. Biotechnol. 42, 1571\u20131580. https:\/\/doi.org\/10.1038\/s41587-023-02024-y (2024).","journal-title":"Nat. Biotechnol."},{"key":"5605_CR42","doi-asserted-by":"publisher","first-page":"W39","DOI":"10.1093\/nar\/gkad426","volume":"51","author":"V Geoffroy","year":"2023","unstructured":"Geoffroy, V. et al. The AnnotSV webserver in 2023: updated visualization and ranking. Nucleic Acids Res. 51, W39\u2013W45. https:\/\/doi.org\/10.1093\/nar\/gkad426 (2023).","journal-title":"Nucleic Acids Res."}],"updated-by":[{"DOI":"10.1038\/s41598-026-36851-1","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T00:00:00Z","timestamp":1768953600000}}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-05605-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-05605-w","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-05605-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T13:38:11Z","timestamp":1769002691000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-025-05605-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,2]]},"references-count":42,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["5605"],"URL":"https:\/\/doi.org\/10.1038\/s41598-025-05605-w","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,2]]},"assertion":[{"value":"12 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 January 2026","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Correction","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A Correction to this paper has been published:","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"https:\/\/doi.org\/10.1038\/s41598-026-36851-1","URL":"https:\/\/doi.org\/10.1038\/s41598-026-36851-1","order":8,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"22894"}}